

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) Budapest (Hungary)

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

Allen H.H., <i>London, Ontario (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piura B., <i>Beer Sheva (Israel)</i>
Balat O., <i>Graziantep (Turkey)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Barber H.K., <i>New York, NY (USA)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Basta A., <i>Krakow (Poland)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Raju K.S., <i>London, England (UK)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Shepherd J.H., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Kubista E., <i>Vienna (Austria)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Tjalma W., <i>Antwerpen (Belgium)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Maggino T., <i>Padua (Italy)</i>	Ungár L., <i>Budapest (Hungary)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Markowska J., <i>Poznan (Poland)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>	Marth C., <i>Innsbruck (Austria)</i>	Vírtej P., <i>Bucharest (Romania)</i>
Di Re F., <i>Milan (Italy)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		Winter R., <i>Graz (Austria)</i>
Fuller A.F. Jr., <i>Boston, MA (USA)</i>		Yokoyama Y., <i>Hirosaki (Japan)</i>

Publishing Organization (M. Morsani):

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

Editorial Office (M. Critelli):

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storie 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three **manuscripts** typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the **Corresponding Author**, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the **title page** (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (purpose of investigation, methods, results, conclusion - about 150 words), **Key words**, **Content** (a 20-word summary), **Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement** (if any), **References, Tables, Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

DISTINGUISHED EXPERT SERIES

- Ovarian cancer Stage IIIC. Consequences of treatment level on overall and progression-free survival** 209
 H. Oksefjell, B. Sandstad, C. Trope - *Montebello, NORWAY*
 The aim of the study was to investigate the influence of hospital level (primary vs secondary care centre), number and timing of surgery and chemotherapy on how radical the surgery was at primary treatment of epithelial ovarian cancer Stage IIIC.
- Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer** 215
 M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa, A. Benedetto, D. Bonifacio, P. Di Bonito, P. Paba, L. Accordi, L. Mariani, S. Syrjänen, C. Favalli, K. Syrjänen, on behalf of the HPV-PathogenISS Study Group - *Turku, FINLAND*
 Down-regulation of E-cadherin was closely associated with progressive CIN and cell proliferation, but did not directly correlate with oncogenic HPV type and did not predict survival in cervical cancer.

EDITORIAL ARTICLE

- Breast cancer treatment - later pregnancy and survival** 225
 M. Kasum - *Zagreb, CROATIA*
 The increasing population of women with BC who delay childbearing may have concerns regarding the effect of treatment on later pregnancy, as well as the influence of pregnancy on the prognosis of disease and their survival.

ORIGINAL ARTICLES

- Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up** 231
 P.A. Argenta, R. Ghebre, K.E. Dusenbery, M.D. Chen, P.L. Judson, L.S. Downs Jr., L.F. Carson - *Minneapolis, MN (USA)*
 Radiation potentiation with cisplatin and paclitaxel results in prolonged survival in high-risk cervical cancer, but toxicity may be prohibitive.
- Radioguided occult lesion localisation in combination with detection of the sentinel lymph node in non-palpable breast cancer tumours** 236
 P. Strnad, L. Rob, M.G. Halaska, J. Chod, A. Zuntova, Z. Moravcova - *Prague, CZECH REPUBLIC*
 The combination of ROLL and SLNB is a possible and safe procedure and when compared with the hook-wire technique, the amount of tissue excision is similar.
- Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions** 239
 N. Jančar, S. Rakar, M. Poljak, K. Fujs, B.J. Kocjan, E. Vrtačnik-Bokal - *Ljubljana, SLOVENIA*
 Laser vaporization, large loop excision of the transformation zone and conization are effective in eliminating high-risk HPV infection.
- Effective chemoradiotherapy protocol with 5-fluorouracil for cervical squamous cell carcinoma *in vitro*** 243
 T. Tanaka, K. Yukawa, N. Umesaki - *Wakayama, JAPAN*
 5FU acts as a radiosensitizer for cervical squamous cell carcinoma and 5FU-sensitivity is reduced in irradiated cells.
- Trastuzumab in metastatic breast cancer** 247
 F. Tomao, E. Miele, G.P. Spinelli, M. Russillo, G. La Ferla, S. Tomao - *Rome, ITALY*
 Trastuzumab, a humanized monoclonal antibody directed against the HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.
- Clinicopathological features of unusual vascular lesions of the pelvis, retroperitoneum and colon in females: a report of five cases and review of the literature** 250
 E. Kairi-Vassilatou, D. Grapsa, K. Kontogianni-Katsarou, V. Smyrniotis, D. Hasiakos, A. Kondi-Pafiti Agatha - *Athens, GREECE*
 Five cases of unusual vascular lesions of the female pelvis, retroperitoneum and colon are presented.

- Proliferative effects of different hormone regimens on mammary glands in ovariectomized rats** 256
 T. Cirpan, O. Iscan, M.C. Terek, S. Ozsener, L. Kanit, S. Pogun, O. Zekioglu, S. Yucebilgin - *Izmir, TURKEY*
 The proliferative effects of different hormone regimens and estrogen receptor modulation on mammary glands in a rat model of surgical menopause are compared.
- Wire localisation biopsy of non-palpable breast lesions: reasons for unsuccessful excision** 262
 E. Kouskos, G.P.H. Gui, D. Mantas, K. Revenas, N. Rallis, Z. Antonopoulou, E. Lampadariou, H. Gogas, C. Markopoulos - *Athens, GREECE*
 An uncommon problem of needle-wire localisation is the failure to identify, localise or excise the breast lesion. In this review article, factors that contribute to the failed needle localisation procedure are presented.
- Cervical-vaginal disease in HIV immunosuppressed patients: management and present screening programme** 267
 L. Di Stefano, G. Coppola, S. Moro, E. Colageo, A. Cellini, G. Coletti - *L'Aquila, ITALY*
 The correlations between cervical lesions, the role of HPV and the clinical and immunological aspects of HIV infection and inflammatory cervical-vaginal disease were studied.
- Endometriosis and possible malignant transformation** 271
 M. Gojnic, V. Dugalic, V. Jeremic, N. Popovic, Lj. Arsenijevic - *Belgrade, SERBIA AND MONTENEGRO*
 Endometriosis is a benign condition characterized by infiltrative growth with a very small, if any, possibility of becoming malignant. Conservative surgery is still one of the main therapy modes, but is mainly reserved for mild cases of the disease.
- Uterine bizarre epithelioid lipoleiomyoma with a myxoid stroma** 273
 K. Takeuchi, S. Kitazawa, T. Tsujino, S. Wakahashi, T. Maruo - *Kobe, JAPAN*
 A rare case of uterine bizarre epithelioid lipoleiomyoma with nuclear atypia within a myxoid stroma is described.
- Surgical management of nipple discharge** 275
 C. Markopoulos, D. Mantas, E. Kouskos, Z. Antonopoulou, K. Lambadariou, K. Revenas, A. Papachristodoulou - *Athens, GREECE*
 Nipple discharge is reported in 2.5 to 3% of women with breast carcinoma. Breast carcinoma is found in approximately 8% of surgically treated patients presenting with bloody nipple discharge.
- Amerindian women of the Brazilian Amazon and STD** 279
 E.B. Brito, I.D.C. Silva, J.N. Stávale, E. Taromaru, R.C. Menezes, S.J. Martins - *Parakanã, BRAZIL*
 Papanicolaou tests, PCR for HPV, *C. trachomatis*, HSV-1/2 and *N. gonorrhoea*, and Hybrid Capture II were performed for high- and low-risk HPV groups during screening for cervical cancer in 49 women of the Parakana tribe.
- DCIS histopathology from a historical perspective** 282
 A.C. Goussia, D.G. Stefanou, E.C. Karaiossifidi, N.J. Agnantis - *Athens, GREECE*
 Historically the definition and terminology associated with the histological types of DCIS have caused confusion. Some data in the literature are reviewed.
- Spontaneous transient rise of CD34 cells in peripheral blood after 72 hours in patients suffering from advanced malignancy with anemia: Effect and prognostic implications of treatment with placental umbilical cord whole blood transfusion** 286
 N. Bhattacharya - *Calcutta, INDIA*
 Umbilical cord whole blood transfusion is safe in cancer patients with anemia. A sustained rise of CD34 levels in some patients may have a positive prognostic effect.

CASE REPORTS

- Third stage ovarian carcinoma - case report: the necessity of a multidisciplinary approach to treatment** 291
 E.M. Messalli, C. Scaffa, G. Mainini, M. Rotondi, E. Pecori, L. Cobellis - *Naples, ITALY*
 A case of third-stage ovarian carcinoma is presented and the necessity of a multidisciplinary approach to treatment is discussed.
- A giant uterine leiomyoma simulating an ovarian mass in a 16-year-old girl: a case report and review of the literature** 294
 D. Grapsa, V. Smyrniotis, D. Hasiakos, K. Kontogianni-Katsarou, A. Kondi-Pafiti, *Athens, GREECE*
 A case of a giant uterine leiomyoma in a 16-year-old girl, which was preoperatively misdiagnosed as an ovarian malignancy, is reported.

- Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report** 297
 P. Klaritsch, O. Reich, S. Regauer, T. Bauernhofer - *Graz, AUSTRIA*
 High-dose chemotherapy seems to be ineffective in patients with endometrial stromal sarcomas.
- Metastases of the digestive tract and ovarian tumors - or vice versa: an analysis** 299
 M. Gojnic, V. Dugalic, V. Jeremic, D. Filimonovic, N. Popovic - *Belgrade, SERBIA AND MONTENEGRO*
 By analyzing ovarian carcinoma cases at three institutions interesting data were obtained: in 38% of the cases metastatic changes were present.
- Case study of a pregnant woman with decidualized ovarian endometriosis whose preoperative findings suggested malignant transformation** 301
 H. Iwamoto, M. Suzuki, N. Watanabe, M. Minai, S. Hirata, K. Hoshi - *Yamanashi, JAPAN*
 A case of decidualized ovarian endometriosis in a pregnant woman is reported. The findings suggest that decidualization of endometriosis can be differentiated preoperatively from malignant transformation.
- Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary - Case Report** 304
 M. Güney, B. Oral, F. Demir, M. Özsoy, N. Kapucuoğlu - *Isparta, TURKEY*
 A rare case of adenocarcinoma arising from the gastrointestinal epithelial elements of BCTO based on microscopic examination and immunohistochemical studies is presented.
- Double laparotomy wound recurrence of endometrial carcinoma** 307
 G.C. Balbi, A. Cardone, A. Monteverde, M. Passaro, L. Montone, R. Rossiello, S. Visconti, M. Battisti, E. Cassese, I. Landino - *Naples, ITALY*
 A case of a 65-year-old woman who had two recurrences in an abdominal incisional scar after total hysterectomy is reported.
- Primary leiomyoma of the ovary in a young woman: literature review and report of a case** 310
 E.E. Ozcimen, M. Oktem, H.B. Zeyneloglu, B.H. Ozdemir, E. Kuscu - *Ankara, TURKEY*
 A case of ovarian leiomyoma in a 32-year-old virgin with the complaint of dysmenorrhea for six months is presented.
- Female adnexal tumor of probable Wolffian origin: clinicopathological, immunohistochemical and cytofluorimetric analyses of a 22-year-old virgin. Case report** 313
 G.C. Balbi, L. Del Piano, D. Labriola, S. Visconti, A. Monteverde, M. Passaro, R. Monaco, A. Cardone, R. Rossiello, S. Panariello, L. Montone - *Naples, ITALY*
 A case of the youngest patient affected by FATWO is reported. At laparotomy the left adnexa, deformed by a well-capsulated mass, was totally removed and sent to the pathologist with a specimen of peritoneal fluid and the omentum.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVII, Number 3, 2006

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher's office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@mgroup-online.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy